Geron Corporation
Geron Corporation develops therapeutics for myeloid hematologic malignancies. Imetelstat, a telomerase inhibitor, is in Phase 3 clinical trials to treat low/intermediate-1 risk MDS and intermediate-2/high-risk myelofibrosis. It inhibits the uncontrolled proliferation of malignant stem/progenitor cells. The company was incorporated in 1990 and is headquartered in California.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |